Our worldwide research, development, manufacturing and marketing activities put AstraZeneca in the global spotlight on a diverse range of issues that affect or concern our stakeholders and society.
We know that effective management of these issues is critical to maintaining trust and confidence in AstraZeneca as a company committed to delivering business success responsibly.
This means having systems in place for identifying the challenges and opportunities associated with our corporate responsibility, together with frameworks and clear accountabilities for managing these consistently and appropriately in line with our strategic objectives.
We continue to use stakeholder engagement and external benchmarking to keep in touch with our external environment and the changing demands of sustainable development. We combine this with internal risk assessment to identify the priorities and inform our strategy development and action planning.
Ensuring compliance is critical to good corporate governance and work in our Compliance and Audit functions is dedicated to ensuring that we deliver on our commitments and continue to have appropriate and effective risk, governance and compliance frameworks in place.
We are making progress, but for a company the size and scope of AstraZeneca, operating within an ever-changing business environment, there will always be work to do to ensure that we consistently and appropriately manage the CR challenges and opportunities associated with our business activities.
Following the recent changes to our management and governance structures, we are reviewing the way in which we will monitor our global activity going forward. Our commitment to GRI reporting will also help to inform this process.
The content of this page was externally assured by Bureau Veritas, February 2009.
Not signed in
Page tools
Share price
- London
-
26.95 GBP - New York
-
44.82 USD
- Stockholm
-
310.10 SEK
At 20-Nov-2009 22:43 GMT
Detailed share price